
    
      This prospective, single-arm trial in patients with refractory metastatic cancer will compare
      the Progression Free Survival (PFS) using a treatment regimen selected by the MCC MTB with
      the PFS (time to tumor progression) for the most recent regimen on which the patient had
      experienced progression (i.e., using patients as their own control).
    
  